Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | LARS1 | Q9P2J5 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30330238 | 1.00 | MAPT (0.41) | MAPTKDM4EGAAALOX5LARS1 | |
| SCHEMBL25166284 | 0.83 | CYP3A4 (0.38) | MAPTALDH1A1 | |
| SCHEMBL30329818 | 0.83 | CYP3A4 (0.38) | MAPTALDH1A1 | |
| SCHEMBL17132321 | 0.75 | MAPT (0.41) | MAPTKDM4EGAALARS1LMNA | |
| SCHEMBL30200188 | 0.75 | ALOX15 (0.50) | MAPTGAAALOX5LARS1LMNA | |
| SCHEMBL8407148 | 0.75 | KDM4E (0.41) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL12000023 | 0.75 | SELL (0.41) | MAPTKDM4EALOX5LARS1ALDH1A1 | |
| SCHEMBL31520283 | 0.75 | MAPT (0.41) | MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL15988846 | 0.75 | ALOX15 (0.50) | MAPTGAAALOX5LARS1LMNA | |
| SCHEMBL9053612 | 0.73 | KDM4E (0.42) | MAPTKDM4EGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | MAPT 2171/4885KDM4E 420/4885GAA 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.